



Clinical trial results:

Phase II study of nilotinib efficacy in Pigmented Villo-Nodular Synovitis / Tenosynovial Giant Cell Tumor (PVNS / TGCT)

Summary

EudraCT number	2010-018869-29
Trial protocol	FR IT NL GB
Global end of trial date	04 October 2013

Results information

Result version number	v1 (current)
This version publication date	20 October 2019
First version publication date	20 October 2019
Summary attachment (see zip file)	PVNS (PIIS1470-2045(18)30143-8.pdf)

Trial information

Trial identification

Sponsor protocol code	ET2009-095
-----------------------	------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01261429
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Centre Léon Bérard
Sponsor organisation address	28 rue Laennec , LYON Cedex 08, France,
Public contact	Centre Léon Bérard S.GUILLEMAUT , Centre Léon Bérard S.GUILLEMAUT , + 4 78 78 28 28, DRCIreglementaire@lyon.unicancer.fr
Scientific contact	Centre Léon Bérard J.Y BLAY , Centre Léon Bérard J.Y BLAY , +33 4 78 78 28 28, DRCIreglementaire@lyon.unicancer.fr

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 June 2014
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	04 October 2013
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study will be to determine the efficacy of 12 weeks (3 months) of nilotinib treatment as measured by the non progression rate (Complete response + Partial Response + Stable disease according to Response Evaluation Criteria In Solid Tumours - RECIST version 1.1) in patients with progressive or relapsing PVNS/TGCT who cannot be treated by surgery.

Protection of trial subjects:

Several follow-up (consultation with physician)

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 December 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 7
Country: Number of subjects enrolled	Netherlands: 16
Country: Number of subjects enrolled	France: 25
Country: Number of subjects enrolled	Italy: 8
Worldwide total number of subjects	56
EEA total number of subjects	49

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	56

From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The inclusion will take during a follow-up consultation of the patient by her oncologist. The investigator will verify the eligibility of the patient, inform him about the study and collect him consent to participation.

Pre-assignment

Screening details:

Patients will be selected among those contacting the study centre for the treatment of PVNS/TGCT according to the inclusion and non-inclusion criteria described above. After being informed of the study and having asked all their questions to the investigator, they will have enough time to decide whether or not they want to be included in the study.

Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Arm title	Treatment with Nilotinib
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Nilotinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

400 mg twice a day
Oral administration

Number of subjects in period 1	Treatment with Nilotinib
Started	56
Completed	56

Baseline characteristics

Reporting groups

Reporting group title	overall trial
-----------------------	---------------

Reporting group description: -

Reporting group values	overall trial	Total	
Number of subjects	56	56	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	56	56	
From 65-84 years	0	0	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	28	28	
Male	28	28	

Subject analysis sets

Subject analysis set title	final statistical analysis
----------------------------	----------------------------

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

All included patients were analyzed for baseline characteristics and efficacy data. Since all these patients have received at least one dose of the study drug, they were also all analyzed for safety data.

Reporting group values	final statistical analysis		
Number of subjects	56		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	56		
From 65-84 years	0		
85 years and over	0		

Gender categorical			
Units: Subjects			
Female	28		
Male	28		

End points

End points reporting groups

Reporting group title	Treatment with Nilotinib
Reporting group description: -	
Subject analysis set title	final statistical analysis
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
All included patients were analyzed for baseline characteristics and efficacy data. Since all these patients have received at least one dose of the study drug, they were also all analyzed for safety data.	

Primary: Endpoint analysis

End point title	Endpoint analysis ^[1]
End point description:	
End point type	Primary
End point timeframe:	
The primary endpoint of the study was the 12-week progression-free rate (12w-PFR).	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There is only one arm, so it is not possible to have a statistical analysis.

End point values	Treatment with Nilotinib	final statistical analysis		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	56	51		
Units: 92.6				
log mean (full range (min-max))	95 (84.3 to 97.9)	95 (84.3 to 97.9)		

Statistical analyses

No statistical analyses for this end point

Secondary: Endpoint analysis

End point title	Endpoint analysis
End point description:	
End point type	Secondary
End point timeframe:	
Secondary endpoints of the study were: 24w-PFR, best overall response (BOR), objective response rate (ORR), duration of response (Drep), progression-free survival (PFS), time to progression (TTP), time to treatment failure (TTF).	

End point values	Treatment with Nilotinib	final statistical analysis		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	48	43		
Units: 89.6				
log mean (full range (min-max))	89.6 (77.3 to 96.5)	89.6 (77.3 to 96.5)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

The investigator immediately informs the sponsor of any serious adverse events occurring during the study in a written report, whether or not they are attributable to the research.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.0
--------------------	------

Frequency threshold for reporting non-serious adverse events: 1 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Adverse events concerned 55/56 patients (98.2%); 54 patients (96.4%) experienced treatment-related adverse events and 6 patients (10.7%) experienced grade 3-4 treatmentrelated adverse events. Serious Adverse Events (SAEs) concerned 3 patients among the 56 included in the study, including one patient not directly concerned (particular case, the wife of the patient was pregnant). Only 1 AE was considered as potentially related to the drug according to the sponsor. No death was reported.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 April 2011	<ul style="list-style-type: none">- to prolong the inclusion period by one year ;- to add the calcium dosage for each biological test.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported